(Q35783032)

10 August 2017

1 reference

title

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer (English)

1 reference

10 August 2017

3

Hartwig Huland

1 reference

10 August 2017

Alexander Haese

1

1 reference

10 August 2017

Markus Graefen

series ordinal

2

1 reference

10 August 2017

Hans Lilja

series ordinal

4

1 reference

10 August 2017

publication date

1 June 2004

1 reference

10 August 2017

published in

Current urology reports

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

231-240

1 reference

Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume

10 August 2017

cites work

1 reference

12 December 2020

Elevated serum prostate specific antigen (PSA) related to asymptomatic prostatic inflammation.

1 reference

12 December 2020

Primary structure of a human glandular kallikrein gene

1 reference

12 December 2020

The value of serum prostate specific antigen determinations before and after radical prostatectomy

1 reference

12 December 2020

PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation

1 reference

12 December 2020

Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2.

1 reference

12 December 2020

Prostate specific antigen: a decade of discovery--what we have learned and where we are going

1 reference

12 December 2020

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

1 reference

12 December 2020

Clinical evaluation of serum prostate-specific antigen-alpha1-antichymotrypsin complex values in diagnosis of prostate cancer: a cooperative study

1 reference

12 December 2020

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146

1 reference

12 December 2020

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

1 reference

12 December 2020

Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies

1 reference

12 December 2020

Diagnosis of Prostatic Carcinoma: The Yield of Serum Prostate Specific Antigen, Digital Rectal Examination and Transrectal Ultrasonography

1 reference

12 December 2020

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis

1 reference

12 December 2020

Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy

1 reference

12 December 2020

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen

1 reference

12 December 2020

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections

1 reference

12 December 2020

Effect of ejaculation on serum total and free prostate-specific antigen concentrations

1 reference

12 December 2020

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

12 December 2020

Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis

1 reference

12 December 2020

A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer

1 reference

12 December 2020

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

12 December 2020

The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels

1 reference

12 December 2020

Characteristics of Prostate Cancer Detected in the American Cancer Society-National Prostate Cancer Detection Project

1 reference

12 December 2020

The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer

1 reference

12 December 2020

Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia

1 reference

12 December 2020

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

12 December 2020

A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.

1 reference

12 December 2020

Systematic sextant biopsies in 651 patients referred for prostate evaluation

1 reference

12 December 2020

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL

1 reference

12 December 2020

An adjustment to the 1997 estimate for new prostate cancer cases

1 reference

12 December 2020

Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum

1 reference

12 December 2020

Capsular penetration in prostate cancer. Significance for natural history and treatment

1 reference

12 December 2020

Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma

1 reference

12 December 2020

Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol

1 reference

12 December 2020

Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease

1 reference

12 December 2020

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.

1 reference

12 December 2020

Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters

1 reference

12 December 2020

Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel

1 reference

12 December 2020

Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics

1 reference

12 December 2020

Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml

1 reference

12 December 2020

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

12 December 2020

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

1 reference

12 December 2020

Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer

1 reference

12 December 2020

The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer

1 reference

12 December 2020

Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA.

1 reference

12 December 2020

Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases

1 reference

12 December 2020

Current trends in prostate cancer diagnosis and staging among United States urologists.

1 reference

12 December 2020

Correlation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populations

1 reference

12 December 2020

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

1 reference

12 December 2020

Radiation injury of the normal and neoplastic prostate

1 reference

12 December 2020

Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy

1 reference

12 December 2020

Free, complexed and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate

1 reference

12 December 2020

Value of the serum prostate-specific antigen-alpha 1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer

1 reference

12 December 2020

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

1 reference

12 December 2020

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer

1 reference

12 December 2020

Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques

1 reference

12 December 2020

A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer

1 reference

12 December 2020

The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer

1 reference

12 December 2020

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum

1 reference

12 December 2020

Current followup strategies after radical prostatectomy: a survey of American Urological Association urologists

1 reference

12 December 2020

Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prost

1 reference

12 December 2020

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

1 reference

12 December 2020

Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia

1 reference

12 December 2020

A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.

1 reference

12 December 2020

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

12 December 2020

Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis

1 reference

12 December 2020

Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL.

1 reference

12 December 2020

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.

1 reference

12 December 2020

Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer

1 reference

12 December 2020

Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry

1 reference

12 December 2020

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer

1 reference

12 December 2020

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

12 December 2020

Prostate-specific antigen and radiation therapy for clinically localized prostate cancer

1 reference

12 December 2020

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients

1 reference

12 December 2020

Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen

1 reference

12 December 2020

Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin

1 reference

12 December 2020

Are T1c tumors different from incidental tumors found at autopsy? The risk and reality of overdetection

1 reference

12 December 2020

Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control

1 reference

12 December 2020

Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen

1 reference

12 December 2020

Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen

1 reference

12 December 2020

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

12 December 2020

Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening

1 reference

12 December 2020

Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR

1 reference

12 December 2020

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age

1 reference

12 December 2020

The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia

1 reference

12 December 2020

Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein.

1 reference

12 December 2020

Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen

1 reference

12 December 2020

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

1 reference

12 December 2020

Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration

1 reference

12 December 2020

Prostate cancer detection at low prostate specific antigen

1 reference

12 December 2020

Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein

1 reference

12 December 2020

Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum

1 reference

12 December 2020

Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2.

1 reference

12 December 2020

Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2.

1 reference

12 December 2020

Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings

1 reference

12 December 2020

Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy

1 reference

12 December 2020

Prostate Cancer Detection in a Clinical Urological Practice by Ultrasonography, Digital Rectal Examination and Prostate Specific Antigen

1 reference

12 December 2020

Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen

1 reference

12 December 2020

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

1 reference

12 December 2020

The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA

1 reference

12 December 2020

Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen

1 reference

12 December 2020

Correlation of pathologic findings with progression after radical retropubic prostatectomy

1 reference

12 December 2020

The National Cancer Data Base report on longitudinal observations on prostate cancer

1 reference

12 December 2020

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

1 reference

12 December 2020

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater

1 reference

12 December 2020

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

1 reference

12 December 2020

Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum

1 reference

12 December 2020

10.1007/S11934-004-0042-6

Identifiers

DOI

1 reference

10 August 2017

1 reference